Estimated penetrance of identified SNPs for their corresponding phenotype

<p><b>Copyright information:</b></p><p>Taken from "Standard linkage and association methods identify the mechanism of four susceptibility genes for a simulated complex disease"</p><p></p><p>BMC Genetics 2005;6(Suppl 1):S142-S142.</p><p>Published online 30 Dec 2005</p><p>PMCID:PMC1866793.</p><p></p

Box whisker plots showing the difference of the CSF biomarker levels according to the positive CSF signature of the “typical” AD core biomarkers Abeta42 and pTAu181.

P-tau: phospho-tau t-tau: total-tau, αSyn: α-Synuclein (αSyn), sTREM2: soluble triggering receptor expressed on myeloid cells 2, GFAP: glial fibrillary acidic protein, YKL40: chitinase-3-like protein 1, S100. (TIF)</p

Baseline characteristics of Parkinson`s Disease (PD) patients and Healthy Controls (HC).

Baseline characteristics of Parkinson`s Disease (PD) patients and Healthy Controls (HC).</p

Receiver Operating Curves (ROC)-curves with Area under the Curve (AUC) values for the tested markers.

No differentiation between the Parkinson’s patients and healthy controls was possible. αSyn, α-synuclein; GFAP, glial fibrillary acidic protein; IL-6, interleukin-6; NfL, Neurofilament light; sTREM2, soluble triggering receptor expressed on myeloid cells 2; YKL40, chitinase-3-like protein 1. (TIF)</p

Spearman’s correlation matrix of the NTK biomarkers, the “typical” AD core parameters, and MoCA Score at the last visit.

p-tau: phospho-tau t-tau: total-tau, αSyn: α-Synuclein (αSyn), sTREM2: soluble triggering receptor expressed on myeloid cells 2, GFAP: glial fibrillary acidic protein, YKL40: chitinase-3-like protein 1, S100, MoCA last visit, Montreal Cognitive Assessment at last visit.</p

Results of the Spearman’s correlation of the NTK biomarkers, the “typical” AD core parameters, and MoCA Score at the last visit.

P-tau: phospho-tau t-tau: total-tau, αSyn: α-Synuclein (αSyn), sTREM2: soluble triggering receptor expressed on myeloid cells 2, GFAP: glial fibrillary acidic protein, YKL40: chitinase-3-like protein 1, S100, MoCA last visit, Montreal Cognitive Assessment at last visit, *p (DOCX)</p

Timepoints of CSF PD sample collections and the assessed markers.

P-tau: phospho-tau t-tau: total-tau, αSyn: α-Synuclein (αSyn), sTREM2: soluble triggering receptor expressed on myeloid cells 2, GFAP: glial fibrillary acidic protein, YKL40: chitinase-3-like protein 1, S100. (DOCX)</p

Longitudinal changes of the CSF levels of the tested markers.

PD: red, HC: green, The gray ribbon gives estimates of the standard error, the solid line gives a loose fit of the measured data points. The figures illustrate that there is no discrimination in PD versus HC with the NTK panel in the longitudinal profile. Time dependence was calculated with a linear mixed model and found no significant longitudinal alteration of the seven Roche NTK biomarkers. αSyn, α-synuclein; GFAP, glial fibrillary acidic protein; IL-6, interleukin-6; NfL, Neurofilament light; sTREM2, soluble triggering receptor expressed on myeloid cells 2; YKL40, chitinase-3-like protein 1.</p

CSF biomarker levels between PD-MCI subjects (MoCA <26) and cognitively unimpaired subjects.

αSyn, α-synuclein; GFAP, glial fibrillary acidic protein; IL-6, interleukin-6; NfL, Neurofilament light; sTREM2, soluble triggering receptor expressed on myeloid cells 2; YKL40, chitinase-3-like protein 1.</p

Top microarray probes.

<p>Probes with FDR-adjusted p-values smaller than 0.05 and with expression differences between PD and control prefrontal cortex BA9 samples greater than 1.5 fold changes. Twenty-one probes (42%) were in genes with FoxO1 transcription factor binding sites. The GENE-E software (<a href="http://www.broadinstitute.org/cancer/software/GENE-E/" target="_blank">http://www.broadinstitute.org/cancer/software/GENE-E/</a>) was used to generate the heatmap.</p